The company is looking especially good after some bad news coming from a rival.For the second day in a row, a pundit's take on Viking Therapeutics (VKTX 3.25%) helped push the biotech's share price higher. It was this rather than inherent news from the company that added more than 3% to said price, a gain that handily beat the S&P 500 index's 0.8% increase. Thumbs-up from bullish punditThe latest analyst to weigh in on Viking's prospects was Morgan Stanley's Michael Ulz, who early Thursday morning published ...